Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZP-531 Phase 1 Study in Healthy, Overweight/Obese, and T2DM Subjects
NCT02040012Phase 1Unknown
- Sponsor
- Alizé Pharma
- Start
- Jul 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing AZP-531 with Placebo (2 arms). Primary endpoint: Number of adverse events. Status: unknown.
02
Drugs
livoletide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02040012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040012.